Clinical Trial Update: Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating post-infusion allogeneic cytokine-induced killer (CIK) cells as consolidative therapy in myelodysplastic syndromes and myelopr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myeloproliferative Disorders

Drugs mentioned

• Cytokine-induced killer (CIK) cells (cytokine-induced killer cells)

Snippet

Sponsor: Everett Meyer | Conditions: Neural Tube Defects, Anemia | Phase 2 | Status: COMPLETED | Results posted: 2019-05-07